932
Views
37
CrossRef citations to date
0
Altmetric
Cardiology: Original Article

Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study

, , , , , & show all
Pages 371-378 | Accepted 03 Jan 2012, Published online: 07 Feb 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (7)

Salam Khalil, Sinan Khayyat, Yasser Al-Khadra & M. Chadi Alraies. (2019) Should all diabetic patients take statin therapy regardless of serum cholesterol level?. Expert Review of Cardiovascular Therapy 17:4, pages 237-239.
Read now
Arrigo F.G. Cicero, Martino Morbini, Marilisa Bove, Sergio D’Addato, Federica Fogacci, Martina Rosticci & Claudio Borghi. (2016) Additional therapy for cholesterol lowering in ezetimibe-treated, statin-intolerant patients in clinical practice: results from an internal audit of a university lipid clinic. Current Medical Research and Opinion 32:10, pages 1633-1638.
Read now
Jaideep Patel, Seth S Martin & Maciej Banach. (2016) Expert opinion: the therapeutic challenges faced by statin intolerance. Expert Opinion on Pharmacotherapy 17:11, pages 1497-1507.
Read now
Aris P Agouridis, Devaki R Nair & Dimitri P Mikhailidis. (2015) Strategies to overcome statin intolerance. Expert Opinion on Drug Metabolism & Toxicology 11:6, pages 851-855.
Read now
Michael M Page & Gerald F Watts. (2015) Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention. Expert Opinion on Emerging Drugs 20:2, pages 299-312.
Read now
Rajesh K Aggarwal & Refai Showkathali. (2013) Rosuvastatin calcium in acute coronary syndromes. Expert Opinion on Pharmacotherapy 14:9, pages 1215-1227.
Read now
Anthony S Wierzbicki, Timothy C Hardman & Adie Viljoen. (2012) Inhibition of pre-protein convertase serine kexin-9 (PCSK-9) as a treatment for hyperlipidaemia. Expert Opinion on Investigational Drugs 21:5, pages 667-676.
Read now

Articles from other publishers (30)

David S. Schade, James Blankenship & R. Philip Eaton. (2023) Maximizing Benefits and Minimizing Adverse Effects of Statins. Endocrine Practice.
Crossref
Nuha A. ElSayed, Grazia Aleppo, Vanita R. Aroda, Raveendhara R. Bannuru, Florence M. Brown, Dennis Bruemmer, Billy S. Collins, Sandeep R. Das, Marisa E. Hilliard, Diana Isaacs, Eric L. Johnson, Scott Kahan, Kamlesh Khunti, Mikhail Kosiborod, Jose Leon, Sarah K. Lyons, Mary Lou Perry, Priya Prahalad, Richard E. Pratley, Jane Jeffrie Seley, Robert C. Stanton & Robert A. Gabbay. (2023) 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 . Diabetes Care 46:Supplement_1, pages S158-S190.
Crossref
. (2022) 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022 . Diabetes Care 45:Supplement_1, pages S144-S174.
Crossref
. (2021) 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021 . Diabetes Care 44:Supplement_1, pages S125-S150.
Crossref
Nirmala Wijekoon, Sanjeewa Wijekoon, Uditha Bulugahapitiya, Nethrani Pathirana, Malintha Wickramasinghe, Shiran Paranavitane, Arosha Kottage, Supun Wijayawardena, Mihipali Karunarathne, Madusha Samarasinghe, Subodha Sumanadasa & Yanushka Herath. (2020) Tolerability and effectiveness of every-other-day atorvastatin compared to daily atorvastatin in patients with muscle symptoms: A randomized controlled clinical trial. Contemporary Clinical Trials Communications 20, pages 100685.
Crossref
. (2020) 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020 . Diabetes Care 43:Supplement_1, pages S111-S134.
Crossref
Cindy Park & Quang Le. (2019) Efficacy and Tolerability of non-daily Statin Administration: A Systematic Review of Literature. Journal of Contemporary Pharmacy Practice 66:1, pages 41-46.
Crossref
. (2019) 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019 . Diabetes Care 42:Supplement_1, pages S103-S123.
Crossref
Alicia J. Jenkins, Emma Scott, Jordan Fulcher, Gary Kilov & Andrzej S. Januszewski. 2019. Comprehensive Cardiovascular Medicine in the Primary Care Setting. Comprehensive Cardiovascular Medicine in the Primary Care Setting 113 177 .
Anthony S. Wierzbicki, Adie Viljoen, Sumarie Viljoen, Steven Martin, Martin A. Crook & Timothy M. Reynolds. (2018) Review of referral criteria to lipid clinics and outcomes of treatment in four UK centres. International Journal of Clinical Practice 72:9, pages e13242.
Crossref
. (2018) 9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2018 . Diabetes Care 41:Supplement_1, pages S86-S104.
Crossref
Monika Kohli, Kinjal Patel, Zofia MacMahon, Radha Ramachandran, Martin A. Crook, Timothy M. Reynolds & Anthony S. Wierzbicki. (2017) Pro-protein subtilisin kexin-9 (PCSK9) inhibition in practice: lipid clinic experience in 2 contrasting UK centres. International Journal of Clinical Practice 71:11, pages e13032.
Crossref
. (2017) 9. Cardiovascular Disease and Risk Management. Diabetes Care 40:Supplement_1, pages S75-S87.
Crossref
Samar O. El-Ganainy, Ahmed El-Mallah, Dina Abdallah, Mahmoud M. Khattab, Mahmoud M. Mohy El-Din & Aiman S. El-Khatib. (2017) Rosuvastatin safety: An experimental study of myotoxic effects and mitochondrial alterations in rats. Toxicology Letters 265, pages 23-29.
Crossref
Negar Maghsoodi & Anthony S. Wierzbicki. (2016) Statin myopathy. Current Opinion in Cardiology 31:4, pages 417-425.
Crossref
Francesca Cortese, Michele Gesualdo, Annamaria Cortese, Santa Carbonara, Fiorella Devito, Annapaola Zito, Gabriella Ricci, Pietro Scicchitano & Marco Matteo Ciccone. (2016) Rosuvastatin: Beyond the cholesterol-lowering effect. Pharmacological Research 107, pages 1-18.
Crossref
David S. Schade, Brendan Cavanaugh, Barry Ramo & R. Philip Eaton. (2016) The Application of the LDL Principle. World Journal of Cardiovascular Diseases 06:05, pages 109-125.
Crossref
. (2016) 8. Cardiovascular Disease and Risk Management. Diabetes Care 39:Supplement_1, pages S60-S71.
Crossref
Tom J. J. Schirris, Tina Ritschel, Albert Bilos, Jan A. M. Smeitink & Frans G. M. Russel. (2015) Statin Lactonization by Uridine 5′-Diphospho-glucuronosyltransferases (UGTs). Molecular Pharmaceutics 12:11, pages 4048-4055.
Crossref
A. Viljoen & A. S. Wierzbicki. (2015) Improving the odds: ezetimibe and cardiovascular disease. International Journal of Clinical Practice 69:4, pages 390-395.
Crossref
Sripal Bangalore, Andrei Breazna, David A. DeMicco, Chuan-Chuan Wun & Franz H. Messerli. (2015) Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability and Risk of Cardiovascular Outcomes. Journal of the American College of Cardiology 65:15, pages 1539-1548.
Crossref
. (2015) 8. Cardiovascular Disease and Risk Management. Diabetes Care 38:Supplement_1, pages S49-S57.
Crossref
Marija Stojanova Jordanov & Hiba Abou Assi. 2015. Lipid Management. Lipid Management 123 147 .
Anthony S Wierzbicki, Dilinika Perera & Mfon Ewang-Emukowhate. (2014) Dyslipidaemia: what's around the corner?. Clinical Medicine 14:Suppl 6, pages s41-s44.
Crossref
Mamta Jaiswal, Ashley Schinske & Rodica Pop-Busui. (2014) Lipids and lipid management in diabetes. Best Practice & Research Clinical Endocrinology & Metabolism 28:3, pages 325-338.
Crossref
. (2014) Standards of Medical Care in Diabetes—2014. Diabetes Care 37:Supplement_1, pages S14-S80.
Crossref
G.B. John Mancini, A. Yashar Tashakkor, Steven Baker, Jean Bergeron, David Fitchett, Jiri Frohlich, Jacques Genest, Milan Gupta, Robert A. Hegele, Dominic S. Ng, Glen J. Pearson & Janet Pope. (2013) Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Working Group Consensus Update. Canadian Journal of Cardiology 29:12, pages 1553-1568.
Crossref
Alyse S. Goldberg, Marianne K. DeGorter, Matthew R. Ban, Richard B. Kim & Robert A. Hegele. (2013) Efficacy and Plasma Drug Concentrations With Nondaily Dosing of Rosuvastatin. Canadian Journal of Cardiology 29:8, pages 915-919.
Crossref
Alyssa J Keating, Kristen Bova Campbell & John R Guyton. (2016) Intermittent Nondaily Dosing Strategies in Patients with Previous Statin-Induced Myopathy. Annals of Pharmacotherapy 47:3, pages 398-404.
Crossref
. (2013) Standards of Medical Care in Diabetes—2013. Diabetes Care 36:Supplement_1, pages S11-S66.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.